Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Global Forum for Qualified Persons for Pharmacovigilance (QPPV)
Session 2: Pharmacovigilance Learnings From Covid-19 – The Pandemic And The Vaccine
Session Chair(s)
Anja Van Haren, MSc
- EudraVigilance Coordinator
- Medicines Evaluation Board (MEB), Netherlands
Magnus Ysander, MD
- EU & UK QPPV & Head Pharmacovigilance Excellence
- AstraZeneca, Sweden
In the current era of the COVID-19 pandemic, the world has never been more interested in pharmacovigilance. Accelerated regulatory approval pathways for COVID-19 vaccines and treatments merits even more rigorous postmarketing surveillance. This session will discuss how the pharmacovigilance network is challenged by for example increased case volumes, innovative signaling methods and new regulatory requirements in a global setting.
Speaker(s)
The UK Vaccination Program – Preparations and Experience from a Regulatory Authority Perspective
Phil Tregunno
- Head of Vigilance Operations, Safety & Surveillance
- Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
A Matter of Volume - Experience from an Industry Perspective
Magnus Ysander, MD
- EU & UK QPPV & Head Pharmacovigilance Excellence
- AstraZeneca, Sweden
PRAC Considerations
Sabine Straus, MD, PhD, MSc
- PRAC Chair, Staff Member
- Medicines Evaluation Board (MEB), Netherlands
Business Continuity in the context of COVID-19 Pandemic
Vicki Edwards
- Vice President, Pharmacovigilance Excellence and International QPPV
- AbbVie, Inc., United Kingdom

Panel Discussion with Q&A
Barbara De Bernardi, MD
- EUQPPV Vice President - Head of Global QPPV Office
- Pfizer S.r.l., Italy
Contact us
Send Email
+41 61 225 51 51
Preconference Workshop
Introduction to the Role of QPPVs
Related events
Advanced Virtual Live Workshop: QPPV Tool Box - Your Key to Success